Bloodstream infections due to Candida species are important complications in severely ill hospitalized patients. This study presents data on species distribution and antifungal susceptibility profiles of Candida bloodstream isolates obtained from Kuwait during a 10-year period. All the bloodstream isolates were identified to species level by the germ tube test and carbohydrate assimilation profile using the VITEK 2 yeast identification system. Using E-test strips for amphotericin B, fluconazole, 5-flucytosine and voriconazole, MICs were determined on RPMI agar supplemented with 2 % glucose. The MIC breakpoints for resistance were based on Clinical and Laboratory Standards Institute criteria or those published by reference laboratories, and were as follows: amphotericin B, >1 μg ml−1; fluconazole, ⩾64 μg ml−1; 5-flucytosine, ⩾32 μg ml−1; and voriconazole, 4 μg ml−1. In all, 607 bloodstream yeast isolates were obtained over the past 10 years in Kuwait. Candida albicans was the predominant species (39.5 %), followed by Candida parapsilosis (30.6 %), Candida tropicalis (12.4 %), Candida glabrata (5.6 %) and Candida krusei (1.6 %). All C. albicans, C. tropicalis and C. glabrata isolates were susceptible to amphotericin B. Of 186 isolates of C. parapsilosis tested, only four (2 %) exhibited an MIC for amphotericin B of >1 μg ml−1. Resistance to fluconazole was observed in nine (3.8 %) C. albicans isolates, two (5.8 %) C. glabrata isolates and four (40 %) C. krusei isolates. Resistance to 5-flucytosine was observed in two (0.8 %) C. albicans isolates, seven (9.3 %) C. tropicalis isolates, three (1.6 %) C. parapsilosis isolates and all ten (100 %) C. krusei isolates. All the isolates of C. albicans, C. tropicalis, C. parapsilosis, C. glabrata and C. krusei were susceptible to voriconazole, including those resistant to fluconazole. Although amphotericin B and fluconazole are widely used in clinical practice in Kuwait, resistance to these drugs remained low.
AhmadS.,
KhanZ.,
MustafaA. S.,
KhanZ. U.2002; Seminested PCR for diagnosis of candidemia: comparison with culture, antigen detection, and biochemical methods for species identification. J Clin Microbiol 40:2483–2489[CrossRef]
AhmadS.,
KhanZ.,
MustafaA. S.,
KhanZ. U.2003; Epidemiology of Candida colonization in an intensive care unit of a teaching hospital in Kuwait. Med Mycol 41:487–493[CrossRef]
BlotS. I.,
VandewoudeK. H.,
HosteE. A.,
ColardynF. A.2002; Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 113:480–485[CrossRef]
EllisM.,
HedstromU.,
JumaaP.,
BenerA.2003; Epidemiology, presentation, management and outcome of candidemia in a tertiary care teaching hospital in the United Arab Emirates, 1995-2001. Med Mycol 41:521–528[CrossRef]
National Committee for Clinical Laboratory Standards2002Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts . Approved standard (M27-A2) Wayne, PA: National Committee for Clinical Laboratory Standards;
OsobaA. O.,
Al-MowalladA. W.,
McAlearD. E.,
HusseinB. A.2003; Candidemia and the susceptibility pattern of Candida isolates in blood. Saudi Med J 24:1060–1063
Ostrosky-ZeichnerL.,
RexJ. H.,
PappasP. G.,
HamillR. J.,
LarsenR. A.,
HorowitzH. W.,
PowderlyW. G.,
HyslopN.,
KauffmanC. A.other authors2003a; Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47:3149–3154[CrossRef]
PfallerM. A.,
JonesR. N.,
MesserS. A.,
EdmondM. B.,
WenzelR. P.1998; National surveillance of nosocomial bloodstream infection due to Candida albicans : frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 31:327–332[CrossRef]
PfallerM. A.,
DiekemaD. J.,
JonesR. N.,
SaderH. S.,
FluitA. C.,
HollisR. J.,
MesserS. A.,
The Sentry ParticipantGroup.2001; International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 39:3254–3259[CrossRef]
PfallerM. A.,
MesserS. A.,
BoykenL.,
HuynhH.,
HollisR. J.,
DiekemaD. J.2002; In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 46:3518–3521[CrossRef]
PfallerM. A.,
DiekemaD. J.,
MesserS. A.,
BoykenL.,
HollisR. J.2003; Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and E-test methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol 41:1440–1446[CrossRef]
PfallerM. A.,
BoykenL.,
MesserS. A.,
TendolkarS.,
HollisR. J.,
DiekemaD. J.2005; Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. J Clin Microbiol 43:5208–5213[CrossRef]
QuindosG.,
RuesgaM. T.,
Martin-MazuelosE.,
SalesaR.,
Alonso-VargasR.,
Carrillo-MunozA. J.,
BrenaS.,
San MillanR.,
PontonJ.2004; In-vitro activity of 5-fluorocytosine against 1,021 Spanish clinical isolates of Candida and other medically important yeasts. Rev Iberoam Micol 21:63–69
RexJ. H.,
PfallerM. A.,
GalgianiJ. N.,
BartlettM. S.,
Espinel-IngroffA.,
GhannoumM. A.,
LancasterM.,
OddsF. C.,
RinaldiM. G.other authors1997; Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro–in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 24:235–247[CrossRef]
SanglardD.,
OddsF. C.2002; Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2:73–85[CrossRef]
SimorA. E.,
GoswellG.,
LouieL.,
LeeM.,
LouieM.1997; Antifungal susceptibility testing of yeast isolates from blood cultures by microbroth dilution and the E test. Eur J Clin Microbiol Infect Dis 16:693–697[CrossRef]
TrickW. E.,
FridkinS. K.,
EdwardsJ. R.,
HajjehR. A.,
GaynesR. P.2002; Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis 35:627–630[CrossRef]